Session » Muscle Biology, Myositis and Myopathies Poster

Date: Tuesday, November 7, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2169

A Two-Center Experience with Rituximab in Patients with Primary Idiopathic Myositis and Overlap Myositis: A Retrospective Observational Study

9:00AM-11:00AM: Abstract Number: 2135

ADAM-17 Is Expressed in the Inflammatory Myopathy, and Is Involved with Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 2139

Analysis of Required Dose of Corticosteroid As Maintenance Therapy and Related Factors in Patients with Polymyositis/Dermatomyositis

9:00AM-11:00AM: Abstract Number: 2132

Angiogenesis and VEGF-Expressing Cells Are Identified Predominantly in the Fascia Rather Than the Muscle in the Early Phase of Dermatomyositis

9:00AM-11:00AM: Abstract Number: 2145

Anti-CXCR3 Antibody Suppresses Inflammation in C Protein-Induced Myositis Model

9:00AM-11:00AM: Abstract Number: 2136

Association of HLA-DQA1*05 with the Presence of Interstitial Lung Disease Independent of Autoantibody Status in Caucasian Patients with Polymyositis and Dermatomyositis

9:00AM-11:00AM: Abstract Number: 2148

Association of the Paraoxonase 1 Q192R Genetic Polymorphism with Disease Activity in Dermatomyositis

9:00AM-11:00AM: Abstract Number: 2142

Autoantibodies Recognizing Cytosolic 5’-Nucleotidase 1A Are Associated with More Severe Disease in Patients with Juvenile Myositis

9:00AM-11:00AM: Abstract Number: 2146

CD4+CXCR4+t Cells in Patients with Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 2173

Characteristics Unique to MDA5 and Anti-Ro/SSA-52 Kda Dual Antibody Positive Patients with Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 2143

Circulating Endothelial Cells and Endothelial Activation Markers As Disease Activity Measures in Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 2133

Clinical Characteristics of the Patients with Recurrent Myositis in Polymyositis and Dermatomyositis: A Retrospective Study

9:00AM-11:00AM: Abstract Number: 2137

Clinical Factors Associated with Long-Term Damage and Calcinosis in an Adult-Age Referral Population of Juvenile Myositis Patients

9:00AM-11:00AM: Abstract Number: 2160

Clinical Significance of Anti-Aminoacyl tRNA Synthetase Antibodies Which Are Positive By ELISA but Not By Immunoprecipitation – the Variations of Antigen Recognition and the Association with Interstitial Lung Diseases but Not Myositis –

9:00AM-11:00AM: Abstract Number: 2172

Clinical Significance of Serum Levels of Anti-Transcriptional Intermediary Factor 1-γ Antibody in Patients with Dermatomyositis

9:00AM-11:00AM: Abstract Number: 2163

Clinical Utilization Patterns and Performance of Commercial Myositis Autoantibody Panels in Routine Practice

9:00AM-11:00AM: Abstract Number: 2176

Clusterin Is Upregulated in Muscle Tissue and Serum in Idiopathic Inflammatory Myopathies and Is Associated with Clinical Disease Activity

9:00AM-11:00AM: Abstract Number: 2161

Comparison of Clinical Characteristics between African American and Caucasian Patients with Polymyositis and Dermatomyositis and Their Response to Conventional Treatment

9:00AM-11:00AM: Abstract Number: 2156

Comparison of Patients with Dermatomyositis in a Specialty Clinic Versus Clinical Trial with Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist

9:00AM-11:00AM: Abstract Number: 2153

Decreased Lean Body Mass and Bone Mineral Density but Increased Body Fat in Myositis Patients Are Associated with Disease Duration, Inflammatory Status, Skeletal Muscle Involvement and Physical Activity

9:00AM-11:00AM: Abstract Number: 2159

Dermatomyositis Acute Onset/Flares Following Ingestion of Isalean® Herbal Supplement: Clinical and Immunostimulatory Findings

9:00AM-11:00AM: Abstract Number: 2168

Dissociation of FVC and Dlco in Patients with Dermatomyositis and Polymyositis

9:00AM-11:00AM: Abstract Number: 2147

Dysphagia in Inflammatory Myositis: A Study of the Structural and Physiologic Changes Resulting in Disordered Swallowing

9:00AM-11:00AM: Abstract Number: 2165

Easily Obtainable Myositis Autoantibody Panel Predictive Factors

9:00AM-11:00AM: Abstract Number: 2167

Efficacy and Safety of Rituximab in Anti-Synthetase Positive and Negative Patients with Idiopathic Inflammatory Myopathy– a Registry-Based Study

9:00AM-11:00AM: Abstract Number: 2154

Efficacy of an Intensive 24-Week Physiotherapy Programme in Patients with Idiopathic Inflammatory Myopathies – Preliminary Data from a Single-Center Controlled Study

9:00AM-11:00AM: Abstract Number: 2157

Factors Associated with Clinical Remission of Skin Disease in Dermatomyositis

9:00AM-11:00AM: Abstract Number: 2171

Functional Measures and Patient Home Self-Assessments in the Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 2158

HLA-DRB1*04:03/*04:06 As the Genetic Susceptibility to Dermatomyositis Positive for Anti-Transcriptional Intermediary Factor 1-γ Antibody in Japanese Population

9:00AM-11:00AM: Abstract Number: 2134

Identification of Multiple Cancer Associated Myositis Specific Antibodies in Idiopathic Inflammatory Myopathies: A Large Longitudinal Cohort Study

9:00AM-11:00AM: Abstract Number: 2140

Infections and Medications Associated with Onset of Myositis in Myovision, a National Myositis Patient Registry

9:00AM-11:00AM: Abstract Number: 2166

Intravenous Immunoglobulins in Idiopathic Inflammatory Myopathies: Efficacy and Predictive Factors for Clinical Response

9:00AM-11:00AM: Abstract Number: 2174

Investigating Exercise- and Crossfit-Induced Rhabdomyolysis: Data from a Community Healthcare System

9:00AM-11:00AM: Abstract Number: 2130

Joint Manifestations in Patients Diagnosed with Idiopathic Inflammatory Myopathy: Multicenter Registry on Inflammatory Myositis from the Rheumatology Society in Madrid, Spain

9:00AM-11:00AM: Abstract Number: 2131

Longitudinal Cohort Study of Anti-PM/Scl Myositis Patients: Mild Muscle and Lung Involvement with Prominent Perivascular Inflammation

9:00AM-11:00AM: Abstract Number: 2144

Multiple Serum Cytokine and Chemokine Profiling to Identify Combinational Biomarkers Toward Patients of Polymyositis/Dermatomyositis Complicated with Rapidly Progressive Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 2152

Mycophenolate Mofetil Treatment with or without a Calcineurin Inhibitor in Resistant Inflammatory Myopathy

9:00AM-11:00AM: Abstract Number: 2155

Myositis As a Complication of Checkpoint Blockade at a Comprehensive Cancer Center

9:00AM-11:00AM: Abstract Number: 2162

Nailfold Videocapillaroscopy in Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 2170

Near Patient Detection of Anti-MDA5 Antibodies Using Photonic Ring Immunoassays

9:00AM-11:00AM: Abstract Number: 2175

Novel Assessment of Interstitial Lung Disease Using the “Computer-Aided Lung Informatics for Pathology Evaluation and Rating” Software System in Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 2138

Predictive Factors for Achievement of Sustained Remission with Polymyositis/Dermatomyositis: A Retrospective Single Center Cohort Study in Japan

9:00AM-11:00AM: Abstract Number: 2164

Prognostic Factors in Polymyositis/ Dermatomyositis Patients with Anti-Synthetase Antibodies

9:00AM-11:00AM: Abstract Number: 2141

Quantitative Nailfold Video Capillaroscopy Parameters Correlate with Dermatomyositis Activity and Damage

9:00AM-11:00AM: Abstract Number: 2150

Serum Microrna-1 Can be a Predictive Marker for Disease Activity of Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 2149

Statin Use in a Longitudinal Cohort of Patients with Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 2151

The Predictive Risk Factors for Opportunistic Infection during Treatment for Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].